This section includes information and resources about Stroke Prevention in Atrial Fibrillation (AF) for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos. For additional information please visit Newshome.
U.S. FDA grants Breakthrough Therapy Designation to Pradaxa® (dabigatran etexilate) specific investigational antidote- For media outside of the U.S., the UK & Canada only
New Pradaxa® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation- For media outside of the U.S., the UK & Canada only
Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate) litigation
Antidote for rapid reversal of Pradaxa® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients
New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients
The Education Hub on Newshome offers the latest information regarding